Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT01672463
Other study ID # HCI57337
Secondary ID
Status Active, not recruiting
Phase Phase 1
First received
Last updated
Start date December 2012
Est. completion date October 2023

Study information

Verified date March 2023
Source Oblato, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an open label Phase 1b clinical trial of IV administration of OKN-007 in a pilot cohort of human recurrent malignant glioma patients. All patients will have been previously treated with the standard-of-care treatment which includes surgical resection, radiation and chemotherapy, and in some cases treatment for recurrent disease with investigational agents or bevacizumab (Avastin). Patients with unequivocal recurrence (first or greater) established by MRI with and without contrast (e.g., Gd-DTPA (Gadolinium-diethylene triamine pentacetic acid) and meeting inclusion and exclusion criteria, will be eligible for OKN-007 treatment on this protocol.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 31
Est. completion date October 2023
Est. primary completion date January 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Confirmed histopathology of WHO grade III glioma or WHO grade IV GBM at primary diagnosis 2. Unequivocal radiographic evidence of tumor progression by MRI within 14 days prior to registration 3. Prior radiotherapy 4. Prior Temozolomide treatment 5. Last cytotoxic chemotherapy 28 or more days or biologic therapy treatment 14 or more days before study start (greater than or equal to 42 days if nitrosourea was administered) 6. Karnofsky performance status greater than or equal to 60% 7. Full recovery (< grade 1) from the toxic effects of any earlier intervention and a minimum of 28 days from the administration of any investigational agent 8. Adequate renal, liver and bone marrow function: - Leukocytes >3,000/mcL - Absolute neutrophil count >1,500/mcL - Platelets >100,000/mcL - Total bilirubin within normal limits - AST / ALT (SGPT) <2.5 x ULN - Creatinine within normal limits 9. Patients must be >_18 years of age Exclusion Criteria: 1. Second primary malignancy (except adequately treated basal cell carcinoma of the skin). Patients who had another malignancy in the past, but have been free of active disease for more than 2 years, are eligible 2. Have received treatment within the last 28 days with a drug that has not received regulatory approval for any indication at the time of study entry 3. Serious concomitant systemic disorders (for example, active infection or abnormal electrocardiogram (ECG) indicative of cardiac disease) that, in the opinion of the investigator, would compromise the safety of the patient and his/her ability to complete the study 4. Patients with moderate or severe renal impairment (calculated creatinine clearance of < 60 mL/min) 5. Patients with sodium, potassium, or creatinine serum electrolytes > grade 2. 6. Patients with PT/PTT above the upper limit of normal 7. Screening ECG abnormality documented by the investigator as medically significant

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
OKN-007
Dose escalation/PK cohort: 20 mg/kg, 40 mg/kg or 60 mg/kg OKN-007 via IV infusion, given 3x/week for the first 4 weeks, then 2x/week for the next 4 weeks, then 1x/week thereafter. Expansion cohort: MTD via IV infusion given 3x/week for the first 4 weeks, then 2x/week for the next 4 weeks, then 1x/week thereafter.

Locations

Country Name City State
United States Oklahoma University Oklahoma City Oklahoma

Sponsors (1)

Lead Sponsor Collaborator
Oblato, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Adverse events per patient The primary objective is to determine MTD, tolerance, and safety of OKN-007 in patients with recurrent GBM and anaplastic glioma. 24 months
Secondary PK level in participants To determine drug levels of OKN-007 in blood. 24 months
Secondary 6 month progression-free survival To determine radiographic response rate and 6 month Progression-Free Survival (PFS) of patients treated with OKN-007. PFS is defined as the time from first drug treatment until objective tumor progression or death. 24 months
See also
  Status Clinical Trial Phase
Recruiting NCT05045027 - Simultaneous Multinuclear Metabolic MRI in Newly Diagnosed or Recurrent Glioma Early Phase 1
Recruiting NCT04323046 - Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults Phase 1
Active, not recruiting NCT04284774 - Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial Phase 2
Recruiting NCT03598244 - Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors Phase 1
Recruiting NCT05278208 - Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors Phase 1/Phase 2
Active, not recruiting NCT03213665 - Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) Phase 2
Active, not recruiting NCT04320888 - Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial Phase 2
Recruiting NCT05139056 - Multiple Doses of Neural Stem Cell Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas Phase 1
Active, not recruiting NCT02208362 - Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma Phase 1
Active, not recruiting NCT02192359 - Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas Phase 1
Unknown status NCT01144988 - Avastin / Irinotecan in Patients With Recurrent or Progressive Malignant Glioma Phase 2
Active, not recruiting NCT03210714 - Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) Phase 2
Active, not recruiting NCT04388475 - Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma Phase 2
Active, not recruiting NCT04195555 - Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) Phase 2
Recruiting NCT05540873 - A Clinical Study of IL13Rα2 Targeted CAR-T in Patients With Malignant Glioma (MAGIC-I) Phase 1
Completed NCT01904123 - STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain Phase 1
Active, not recruiting NCT02658279 - Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype N/A
Withdrawn NCT04521946 - Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer Phase 1
Recruiting NCT04214392 - Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma Phase 1
Recruiting NCT03896568 - MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma Phase 1